Journal of the Society for Information Display 28.4 (2020): 324-332.
Tentech announced on the 7th that it was finally selected as the lead organization for the Health and Medical Technology R&D project with 'OLED Electronic Medication‘.
Chronic inflammatory skin disease, a representative environmental disease, is on the rise worldwide due to the recent increase in pollution and allergens due to industrialization. Atopic dermatitis has increased to 138 million people worldwide by 2022, and psoriasis is a chronic inflammatory skin disease with 125 million reported cases.
Steroid ointment is commonly used to treat atopy and psoriasis. It is simple and inexpensive, but the disadvantage is that there are many side effects when used for a long period of time. In addition, although recently developed biologics have attracted attention, they have problems such as high cost and not proven safety in long-term use. Phototherapy using ultraviolet rays (UVA/B) is also a relatively safe, effective, and economical treatment, but it has to be visited directly at the hospital 2-3 times a week, and in the case of children, it is not used in a limited way because they cannot enter the treatment unit alone.
As a new treatment to improve these shortcomings, 'OLED e-medication’ is attracting attention. OLED, which has recently been spotlighted as a next-generation light source and is being commercialized, has an ideal surface light source shape and can be irradiated uniformly over a large area. In addition, it is possible to implement a "stick-on" patch type that is in close contact with the human body or a product that can be deformed along with the movement of joints such as wrists and knees which does not cause overheating issues.
According to Tentech, the purpose of this task is to develop a wearable OLED e-medication for the treatment and management of chronic inflammatory skin diseases.
A Tentech official said, "If we develop a new concept of wearable OLED e-medication that can be treated anytime, anywhere, we expect that it will be an effective and convenient treatment compared to existing drugs or medical devices." “We will do our best to develop OLED electronic drugs in cooperation with Gil Hospital and Gachon University,” he said.
Tentech is preparing to go public on the KOSDAQ in the first half of next year with 10Thera, a 2 Line HIFU device, and 10Therma, a monopolar high frequency device to be released next month.